Results 131 to 140 of about 49,657 (223)

Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. [PDF]

Clin Drug Investig, 2020
Khalilieh S, Yee KL, Sanchez R, Stoch SA, Wenning L, Iwamoto M.   +5 more
europepmc   +1 more source

Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation

, 2002
Miguel E. Quiñones‐Mateu, Mahlet Tadele, Mariona Parera, Antonio Más, Jan Weber, Héctor R. Rangel, Bikram Chakraborty, Bonaventura Clotet, Esteban Domingo, Luis Menéndez‐Arias, Miguel Ángel Martı́nez   +10 more
openalex   +1 more source

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. [PDF]

Drugs Context, 2020
Pham HT, Xiao MA, Principe MA, Wong A, Mesplède T.   +4 more
europepmc   +1 more source

Human Immunodeficiency Virus Mutagenesis during Antiviral Therapy: Impact of Drug-Resistant Reverse Transcriptase and Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors on Human Immunodeficiency Virus Type 1 Mutation Frequencies

, 2005
Renxiang Chen, Masaru Yokoyama, Hironori Sato, Cavan Reilly, Louis M. Mansky   +4 more
openalex   +1 more source

Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants.

J Mater Chem B, 2022
Shakil A, Hern FY, Liu C, Temburnikar K, Chambon P, Liptrott N, McDonald TO, Neary M, Owen A, Freel Meyers C, Rannard SP.   +10 more
europepmc   +1 more source

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study

, 2018
А В Кравченко, Elena Orlova‐Morozova, Tatiana Shimonova, О. А. Козырев, Ф. И. Нагимова, Nataliya Zaharova, Э. С. Иванова, У. А. Куимова, А. А. Попова, Oksana Chernova, O. S. Tonkih, Д. А. Гусев, A. A. Yakovlev, Vadim Pokrovsky, Вадим В. Бычко, Natalia Vostokova   +15 more
openalex   +2 more sources

Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients. [PDF]

Infect Dis Poverty, 2020
Chen S, Han Y, Song XJ, Li YL, Zhu T, Lu HZ, Tang XP, Zhang T, Zhao M, He Y, He SH, Wang M, Li YZ, Huang SB, Li Y, Liu J, Cao W, Li TS.   +17 more
europepmc   +1 more source

Molecular dynamics simulations and docking of non-nucleoside reverse transcriptase inhibitors (NNRTIs): a possible approach to personalized HIV treatment [PDF]

, 2012
Florian D. Roessler, Oliver Korb, Andreas Bender, Werner Maentele, Peter J. Bond   +4 more
openalex   +1 more source

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV [PDF]

, 2020
D.M. Himmel, Eddy Arnold
openalex   +1 more source

Nucleoside Reverse Transcriptase Inhibitors, Mitochondrial Dna and Aids Therapy [PDF]

, 2005
William Lewis
openalex   +1 more source